Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet”

Executive Summary

In an interview with "The Pink Sheet," Charles Baum highlights several of Pfizer's late-stage oncology drugs in development, including axitinib in pancreatic cancer and tremelimumab for metastatic melanoma, and discusses the way Pfizer's R&D strategy for oncology is evolving. Baum is VP and head of the Oncology Therapeutic Area at Pfizer Global Research. Prior to joining Pfizer in 2003 he was senior director of oncology at Schering-Plough.

You may also be interested in...

AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval

More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.

Pfizer Restructures for a More Flexible Future

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.

Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model

Following a strategic review of Bristol-Myers Squibb's business, the company's management unveiled a productivity initiative Dec. 5 designed to cut $1.5 billion in costs and fashion the drug maker into a "next-generation biopharma.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts